GO
Loading...

Biotechnology

More

  • Sanofi-Aventis CEO: We've Been Quick to Move Friday, 13 Apr 2012 | 10:50 AM ET

    Sanofi-Aventis has been quick to move before its patents on bestselling products expired, said CEO Chris Viehbacher.

  • Cramer's Growth Play on Celgene   Thursday, 12 Apr 2012 | 6:45 PM ET
    Cramer's Growth Play on Celgene

    Mad Money's Cramer runs through a ten-point checklist to see if Celgene is in a position to deliver growth to investors.

  • The Trade Behind Allergan's Pullback, Cramer   Thursday, 12 Apr 2012 | 6:25 PM ET
    The Trade Behind Allergan's Pullback, Cramer

    Cramer's analysis on Allergan shows that it's a high-quality stock that can be bought into weakness.

  • Celgene Riding Molecular Biology 'Revolution': CEO Thursday, 12 Apr 2012 | 5:31 PM ET
    E. Coli

    Investors are suddenly hot for biotechnology, and that helps Celgene, CEO Robert Hugin told CNBC Thursday.

  • Celgene CEO on Health Care Growth   Thursday, 12 Apr 2012 | 3:20 PM ET
    Celgene CEO on Health Care Growth

    The S&P Biotech Index is up more than 10 percent and Celgene is one of its biggest gainers. Robert Hugin, Celgene chairman & CEO, discusses what's driving the company's growth, including its recent acquisition of Avila Therapeutics.

  • Injectable Cholesterol Drugs Expected to be a Game Changer

    CNBC's Seema Mody has the details on Regeneron Pharmaceuticals and Amgen releasing data on injectable drugs.

  • Most Productive Cities Tuesday, 28 Feb 2012 | 5:52 PM ET
    The Brookings Institution recently issued a report the compared per-capita gross domestic product and changes in employment data from 2010 to 2011 in 200 of the world’s largest metropolitan areas. The report found that these areas produced 48 percent of global output despite accounting for only 14 percent of the world’s population and employment.In other findings: Ninety percent of the fastest-growing economies were outside North America and western Europe; U.S. metropolitan areas outperformed t

    The Brookings Institution analyzed the financial data of the world’s largest metropolitan areas and uncovered some interesting findings. Check out which cities were the most productive.

  • Making Money Without the Speculation Rush Friday, 24 Feb 2012 | 5:32 PM ET
    mm_avatar_100_cramer.jpg

    Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.

  • Six out of the 10 patients treated for hepatitis C with a combination of Gilead Science’s experimental drug GS-7977 relapsed, the company disclosed Friday. “This is just par for the course. There’s a reason people do trials on their drugs. You don't know what the answer is until you get the data,” said ISI analyst Mark Schoenebaum, who has a “buy” rating on Gilead.

  • 6 Stocks Unworthy of Biotech Bull Market Wednesday, 8 Feb 2012 | 10:57 AM ET

    Investors are riding a wave of unprecedented optimism following what seems like an avalanche of biotech deals, early drug approvals, and positive clinical news that has kicked off the year. TheStreet.com reports.

  • Cramer Slaps a ‘Buy’ on Biogen Friday, 27 Jan 2012 | 9:02 PM ET

    Find out why he’s bullish on this biotech name.

  • Cramer: Biogen Idec's Profit Pipeline   Thursday, 26 Jan 2012 | 6:25 PM ET
    Cramer: Biogen Idec's Profit Pipeline

    Mad Money's Cramer, takes a look at Biogen Idec's medical breakthrough drugs and its near-term catalysts for growth this year.

  • Finerman's Fine Print: Roche Hostility   Wednesday, 25 Jan 2012 | 5:18 PM ET
    Finerman's Fine Print: Roche Hostility

    Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.

  • Cramer's Speculative Biotech Play: Regeneron   Tuesday, 10 Jan 2012 | 6:15 PM ET
    Cramer's Speculative Biotech Play: Regeneron

    Len Schleifer, Regeneron Pharmaceuticals CEO, discusses smart biotech investing and growth prospects in the company's pipeline, with Mad Money's Jim Cramer.

  • Which Biotech Company Is the Next Takeover Target? Monday, 9 Jan 2012 | 5:52 PM ET
    stethoscope_money_200.jpg

    As the JPMorgan Health Care conference kicks off this week, one question remains for investors in the biotech space. What’s the next takeover target as large drug makers look to build out their pipeline?

  • Health Care & the State of Biotech   Monday, 9 Jan 2012 | 5:19 PM ET
    Health Care & the  State of Biotech

    Richard Pops, Alkermes chairman & CEO, discusses the challenges facing the health care industry; FDA approval of a once weekly diabetes drug, and other promising new drug candidates.

  • 2011 Top Stocks: No. 5 Biogen Idec Wednesday, 28 Dec 2011 | 2:59 PM ET

    The No. 5 performer in the top S&P stocks of 2011 could see more growth ahead, one “Fast Money” pro said.

  • Bulls Seek Major Rebound From Targacept Tuesday, 13 Dec 2011 | 6:02 AM ET

    Targacept has been exiled to the woodshed, but yesterday the buyers came back in force.

  • Questcor: A Cheap Biotech Stock Thursday, 17 Nov 2011 | 6:55 PM ET

    Cramer goes one-on-one with Questcor CEO Don Bailey to find out more about the company.

  • ImmunoGen CEO on New Breast Cancer Drug Monday, 26 Sep 2011 | 6:49 PM ET

    Daniel Junius talks to Cramer about the drug’s recent trial, which was good news for the company’s stock, and when the FDA could get it for approval.